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Genomewide association studies (GWAS) have identified over 100 loci containing single 
nucleotide variants (SNVs) that influence the risk of developing multiple sclerosis (MS). Most 
of these loci lie in non-coding regulatory regions of the genome that are active in immune cells 
and are therefore thought to modify risk by altering the expression of key immune genes. To 
explore this hypothesis we screened genes flanking MS associated variants for evidence of 
allele specific expression (ASE) by quantifying the transcription of coding variants in linkage 
disequilibrium with MS associated SNVs. In total, we were able to identify and successfully 
analyse 200 such coding variants (from 112 genes) in both CD4+ and CD8+ T cells from 106 
MS patients and 105 controls. Fifty-six of these coding variants (from 43 genes) showed 
statistically significant evidence of ASE in one or both cell types. In the Lck interacting 
transmembrane adaptor 1 gene (LIME1), for example, we were able to show that in both cell 
types, the MS associated variant rs2256814 increased the expression of some transcripts while 
simultaneously reducing the expression of other transcripts. In CD4+ cells from an additional 
independent set of 96 cases and 93 controls we were able to replicate the effect of this SNV on 
the balance of alternate LIME1 transcripts using qPCR (p=7x10-10). Our data thus indicate that 
some of the MS associated SNVs identified by GWAS likely exert their effects on risk by 
distorting the balance of alternate transcripts rather than by changing the overall level of gene 
expression. 
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Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system with a 
complex aetiology. Through genome wide association screening (GWAS) more than 100 
susceptibility loci have been identified with the vast majority mapping to non-coding 
regulatory regions of the genome that are active in immune cells.1,2 The fact that very few of 
the identified associations seem to be driven by protein coding changes suggests that most of 
these variants likely exert their effects by altering the expression of key genes in critically 
important cell types.3 The overlap between MS associated loci and epigenetic markers of active 
regulation is particularly high in T cells suggesting that many genes likely exert their relevant 
effects within this cell type.4 Collaborative efforts such as the International Human Epigenome 
Consortium (IHEC, http://ihec-epigenomes.org/) and the Genotype-Tissue Expression 
Consortium (GTEx)5 have firmly established the pervasive effects of genetic variation on gene 
expression and have shown that while many single nucleotide variants (SNVs) influence tightly 
linked proximal genes (cis effects) in a range of cell types, others exert cell type specific and 
longer range (trans) effects.6 It is also recognised that some of these genotype dependent 
regulatory effects are only apparent in particular contexts, such as when cells are stimulated7 
or come under the influence of particular environmental factors.8 Very little of these epigenetic 
data are disease specific, leaving unanswered questions regarding the effects of associated 
variants in the context of the disease to which they predispose. To explore more specifically 
the effects of MS associated variants on the transcriptional regulation of proximal genes, we 
quantified the allele specific expression (ASE) of coding variants mapping within such genes 
that are in high linkage disequilibrium (LD) with their respective MS SNVs using a targeted 
next generation sequencing approach, which not only increases the sensitivity of detecting cis-
regulatory effects but also allows for the detection of low abundance mRNA that can be missed 
in RNAseq analysis.9 In heterozygous individuals, the transcription of the risk allele is 
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quantified relative to the transcription of the alternate allele, which provides an internal control 
correcting for external factors such as trans-acting factors and environmental influences that 
can confound cis-eQTL analysis,10 particularly in the presence of negative feedback 
mechanisms. The ASE approach has been successfully applied in other diseases11,12 and is 
expected to be more sensitive and specific in the context of disease.13,14 Based on this we 
elected to search for ASE in lymphocyte subtypes that are likely to be relevant in MS (CD4+ 
and CD8+ T cells) in both healthy individuals and patients with MS. 
Materials and Methods 
Samples 
We recruited 202 individuals with MS from our local specialist Clinic and 198 healthy control 
individuals from the NIHR Cambridge BioResource. Cases and controls were all of Northern 
European descent and were matched for gender and age. Sample characteristics are outlined in 
Table 1. In the screening stage, we included 106 cases and 105 controls. The remaining 189 
individuals (96 cases and 93 controls) were utilised for replication analysis. The study was 
approved by the Ethics Committee of the University of Cambridge (REC-11/33/0007, controls) 
and the NRES Committee South Central – Berkshire (REC-06/MRE12/11, cases) and all 
subjects gave fully informed valid consent. All of these subjects had been previously genotyped 
enabling identification of heterozygotes at each SNV of interest. 
Cell isolation and cDNA synthesis 
We collected 50ml of heparinised venous blood from each study subject and then isolated 
peripheral blood mononuclear cells (PBMCs) using Ficoll density-gradient centrifugation. 
CD4+ and CD8+ T cells were isolated using magnetic activated cell sorting (MACS) according 
to the manufacturers’ instructions (Miltenyi Biotec). Specifically, CD3+ cells were negatively 
selected using a Pan T Cell Isolation Kit followed by positive selection of CD8+ cells with the 
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remaining fraction representing CD4+ cells. The purity of the separated cells was checked by 
flow cytometry for a subset of the samples, with a mean purity of >90% for CD4+ T cells and 
>95% for CD8+ T cells. The isolated cells were immediately lysed in TRIzol® reagent 
(Thermo Fisher Scientific), total RNA extracted according to the standard TRIzol protocol and 
genomic DNA contamination removed using DNase I treatment (Thermo Fisher Scientific). 
The extracted RNA was cleaned using the RNeasy MinElute Cleanup Kit (Qiagen), assessed 
for integrity using an Agilent 2100 Bioanalyser and then quantified using a Nanodrop 1000. 
For each subject 2µg of total RNA was reverse transcribed using SuperScript III (Thermo 
Fisher Scientific) according to the manufacturer’s protocol with a 1:1 mixture of random 
hexamers and oligo dT primers. In parallel genomic DNA was isolated from peripheral blood 
utilising the DNeasey Blood and Tissue kit (Qiagen) and quantified using a Nanodrop 1000. 
SNV selection 
Considering genes lying within 0.25cM of the 110 associated SNVs identified in the MS 
Immunochip study,2 and using the 1000 genomes CEU/GBR Phase I population data together 
with the Variant Effect Predictor tool in Ensembl release 76, we identified 305 coding variants 
that were in high LD with an MS associated SNV (r2>0.7). Primers were designed to amplify 
the sequence containing the coding variants of interest in both cDNA and genomic DNA 
(gDNA). For a subset of SNVs (n=29) sequence restrictions meant that independent primers 
had to be designed to amplify cDNA and gDNA. All primers were designed using 
Primer3Plus15 and checked using the UCSC in-silico PCR tool. Due to sequence constraints 
we were unable to be design primers for 36 of the SNVs and initial testing failed for a further 
9. The remaining 260 variants were taken forward for sequencing. A full list of the SNVs 
considered is shown in Supplementary Table S1. 
PCR amplification and sequencing 
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For each of the 260 coding SNVs we utilised the existing genotyping data to identify 
heterozygous individuals and then amplified the sequence containing the SNV in CD4+ and 
CD8+ T cell derived cDNA and the gDNA.  PCR amplification was performed using Amplitaq 
Gold 360 mastermix containing either 10ng CD4 or CD8 derived cDNA or 20ng gDNA, 1uM 
forward and 1uM reverse primer in a total volume of 5ul. The reaction conditions were 95°C 
for 10 mins followed by 40 cycles of: 95°C for 30 secs, 60°C for 30 secs, 72°C for 30 secs and 
a final extension stage of 72°C for 7 mins. For each individual the PCR products from all SNV 
containing sequence fragments were combined into cell type specific pools, such that three 
pools were generated from each individual; CD4+ cDNA, CD8+ cDNA, and gDNA. These 
pooled PCR products were cleaned using ExoSAP-IT (Affymetrix) according to the 
manufacturer’s instructions. A second PCR to add the indexed Illumina adapters allowing 96-
plex pooling was then completed. This indexing PCR was completed in a total volume of 10ul, 
containing 2ul of the cleaned cell specific pooled PCR product and 200nM each of forward and 
reverse Illumina indexed primers. The reaction conditions were 95°C for 10 mins followed by 
20 cycles of: 95°C for 30 secs, 54°C for 30 secs, 72°C for 1 min and a final extension stage of 
72°C for 5 mins. The 96 indexed samples (comprising 32 individuals x 3 pools) were combined 
and cleaned using QiaQuick PCR purification kit (Qiagen). The samples were then sequenced 
using PE300 reads on the Illumina MiSeq. Due to low library diversity, a phiX spike in of 20% 
and between 5-10pM of product was loaded onto the MiSeq. 
Data pre-processing and ASE analysis 
Adapter sequences were removed using CutAdapt v1.1616 and the paired reads merged using 
FLASH v1.2.917, low quality bases were trimmed using Trimmomatic v0.3618 and aligned to 
the human reference genome (Homo_sapiens.GRCh38.dna.primary_assembly) using BWA-
MEM v0.7.17.19 Variant calling and allele read counts were generated using SAMtools v1.8 
and BCFtools v1.8.20 At each variant site, samples with read counts less than 30 were excluded 
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from analysis. The ratio of the risk allele to total read count was established for each SNV in 
the CD4, CD8 and gDNA sample. Given that the expected ratio is 0.5 in the gDNA sample, 
the observed ratio in this sample provided a means to compensate for any allele specific PCR 
bias in sequencing and/or reference allele alignment bias. Individual samples were excluded if 
the gDNA assay failed or if the observed gDNA allelic ratio deviated by more than 12.5% from 
the median across all other samples for that SNV; resulting in an average of 3 samples being 
excluded per tested coding SNV. The CD4+ and CD8+ ratios were then normalised according 
to the mean risk allele ratio seen in the gDNA for each SNV and the ASE effect size defined 
as the ‘normalised risk allele ratio – 0.5’. Statistical support for ASE was tested using a paired 
two-tailed t-test between the normalised gDNA and cDNA risk allele ratios. Statistical support 
for case-control and cell type specific differences in ASE were assessed using an un-paired 
two-tailed t-test. A conservative Bonferroni correction factor of 1000 (200 SNPs x 5 tests) was 
applied giving a nominal statistical significance level of p<5x10-5. These data have been 
deposited in the European Genome-phenome Archive (EGA) which is hosted by the EBI and 
the CRG, under accession number EGASXXXXXXXXXXX. 
Replication analysis 
To validate and replicate the ASE we observed in the LIME1 gene we repeated the analysis 
using qPCR in an independent second cohort of 96 cases and 93 controls. Specifically, we 
designed primers to detect rs914559 carrying transcript (forward primer – 
GGCCCGAGGACGCTGTA, reverse primer – AGGTGGGTCCGCCTCAGTA, probe – 
6FAM-CGACCAGCCTTCCT) and rs2236510 carrying transcripts (forward primer – 
GGCAGAGCAGCCCTAGTTCA, reverse primer – TCTCCCGTTCCAGCTCTGACT, probe 
– 6FAM-CCCCGCCAGAAGG) using Taqman methodology on a Quantstudio 7K Flex and 
data analysed using the Quantstudio Real-Time PCR Software. The PCR reaction was set up 
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according to the manufacturer’s instructions with 20ng of cDNA and normalised against the 
combined expression of the β-actin (ACTB) gene (Hs99999903_m1, Thermo Fisher Scientific). 
 and the 18S ribosomal RNA (Hs99999901_s1, Thermo Fisher Scientific).21 All samples were 
processed blind to genotype. A regression analysis of the resulting data including age and 
gender as covariates was completed in PLINK.22 
Results 
To investigate the cis regulatory effects of the MS associated SNVs, we searched for evidence 
of ASE in coding SNVs that were strong proxies for MS associated variants in CD4+ and CD8+ 
T cells collected from 106 MS patients and 105 controls. Targeted re-sequencing was attempted 
for 260 proxy coding variants. Following quality control (as described in the methods) we 
identified and excluded a total of 60 SNVs with inadequate data quality; 41 SNVs where there 
were less than 5 individuals with paired CD4 or CD8 and gDNA data, 2 SNVs with very 
extreme sequencing bias in the gDNA sample (risk allele ratio was < 0.3 or > 0.7) and 17 SNVs 
where it was impossible to accurately align sequence (most frequently because of 
pseudogenes). We successfully analysed the remaining 200 coding SNVs (from 112 genes) 
that were in high LD (r2>0.7) with 60 of the 110 MS associated variants identified in the MS 
Immunochip study.2 At a Bonferroni corrected conservative significance threshold of p<5x10-
5, we found statistically significant evidence for ASE at 38 of these SNVs in both cell types 
(see Table 2), 7 in CD4+ alone and 11 in CD8+ alone (see Supplementary Table S2). These 56 
significant ASE variants were located in 29 of the 60 MS regions investigated and implicated 
43 genes. The full list of all SNVs investigated and the final number of heterozygous sample 
analysed for each SNV is provided in Supplementary Table S2 and Supplementary Figures. 
The strongest ASE we identified in CD4+ T cells was for the known splice site variant within 
the TNF Receptor Superfamily Member 1A gene (TNFRSF1A) rs1800693 
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(NC_000012.12:g.6330843T>C). Carriage of the risk allele (rs1800693_G) has previously 
been shown to increase the expression of a transcript lacking exon 6, which codes for a soluble 
version of the receptor.23,24 Using our approach, we could not directly interrogate this Δ6 
transcript but were able to quantify the expression of the non-coding transcript 
ENST00000535038.1 as this includes the retained intron in which rs1800693 is located and 
therefore transcribed. We found that the MS risk allele results in increased expression of this 
non-coding transcript, with consistent ASE identified across all the heterozygous samples in 
both CD4+ cells (n=97, ASEeffect = 0.17, p=8.6x10
-53) and CD8+ cells (n=98, ASEeffect = 0.18, 
p=1.1x10-53). Within the same region we also investigated a second proxy coding SNV within 
TNFRSF1A (rs767455; NC_000012.12:g.6341779T>C ) which lies within exon 1 and captures 
all 11 known transcripts of TNFRSF1A and is in tight LD with rs1800693 (r2=0.79). However, 
for this SNV the evidence for ASE was not consistent across all heterozygous individuals and 
did not reach significance (see Supplementary Table S2). These data, illustrate the sensitivity 
of ASE to identify disease relevant transcripts in MS. 
On Chromosome 20 we identified a novel region of ASE, where the genomic architecture of 
local genes conveniently intersected with the position of usable proxy variants thereby allowing 
us to quantify individual transcripts and subsets of transcripts. Within this region the MS 
associated SNV rs2256814 (NC_000020.11:g.63742630G>A) is tagged by six proxy coding 
SNVs from three genes: two in the zinc finger CCCH-type and G-patch domain containing 
gene (ZGPAT); two in the Lck interacting transmembrane adaptor 1 gene (LIME1); and one in 
the SLC2A4 regulator gene (SLC2A4RG), this last variant being the MS associated SNV 
rs2256814 itself. We found no statistically significant evidence for ASE in either ZGPAT or 
SLC2A4RG, whereas both the proxy coding variants in LIME1, rs914559 
(NC_000020.11:g.63737947C>A) and rs2236510 (NC_000020.11:g.63737451C>T), showed 
statistically significant evidence for ASE (see Figure 1). Notably these proxy variants lie in 
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different transcripts and show opposite effects with respect to the MS risk allele, this allele 
increasing expression of transcripts containing rs914559 (ENST00000487026.5, 
ENST00000465591.1) and reducing expression of transcripts containing rs2236510 
(ENST00000493265.2 and ENST00000621325.1). To confirm these initial findings, we 
designed transcript specific primers and completed an expression analysis using Taqman 
methodology. In an independent replication cohort of 96 cases and 93 controls we confirmed 
the effects of the MS risk variant on LIME1 transcript balance in CD4+ cells (see Figure 2). 
Due to the exon structure surrounding the SNVs of interest, we could not establish whether the 
ASE was restricted to the protein coding or non-coding transcripts.  
For 29 ASE SNVs common primers could not be designed for both the cDNA and gDNA (see 
Supplementary Table 1), therefore potential amplification bias or copy number variation could 
potentially bias the results. Of these 29 SNVs, 21 were successfully analysed and 5 showed 
significant evidence of ASE in either CD4 or CD8 cells: rs28445040 
(NC_000002.12:g.230245867C>T) in SP140; rs1054283 (NC_000008.11:g.78698475A>T) in 
ZC2HC1A; rs6897932 (NC_000005.10:g.35874473C>T) in IL7R; rs1883832 
(NC_000020.11:g.46118343T>C) in CD40 and rs8033595 (NC_000015.10:g.90540121G>A) 
in CRTC3. All of these SNVs have been identified as eQTLs in GTEx V8 (see Supplementary 
Table 2) with the direction of effect consistent to that we observed. 
Amongst our top ASE findings 17 relate to long non-coding RNA (lncRNA) transcripts. Such 
molecules are often only expressed at low levels25  and are suggested to be involved in 
transcriptional regulation, particularly of the protein coding genes that they overlap  in a cell 
type specific manner.26 One of the most significant of such findings related to the SNV 
rs4078410 (NC_000002.12:g.112055265T>C) that we used as a proxy for the nearby MS 
associated SNV (rs17174870; NC_000002.12:g.111907624C>T) and in the latest Gencode 
V32 release lies in the lncRNA RNA AC093675.1. This lncRNA overlaps in an antisense 
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direction in the 5’UTR of the transmembrane protein 87B gene (TMEM87B). Little is known 
about TMEM87B beyond its potential interaction with Human Papilloma Virus Type 1827 and 
its possible relevance in modulating endosome to trans-Golgi network transport.28 At the same 
locus, and centromeric to TMEM87B, lies the MER proto-oncogene, tyrosine kinase gene 
(MERTK), which is perhaps a more obvious candidate for MS given its established role in the 
clearance of apoptotic cells by phagocytosis.29 Future studies on the role of these lncRNAs in 
disease is required to establish their functionality and the gene(s) they may regulate. 
Notable we saw no evidence for any corrected statistically significant difference in ASE 
between cases and controls, in either CD4+ or CD8+ T cells. However, one of most highly 
ranked SNVs showing differential expression in CD4+ T cells between cases and controls was 
rs914559 in LIME1 (p=0.005) where the ASE effect size was greater in MS patients (ASEeffect 
= 0.17) than in healthy controls (ASEeffect = 0.12). Likewise, only one corrected statistically 
significant cell type specific ASE was observed, which related to the coding proxy rs2272697 
(NC_000004.12:g.102634835A>G) in the Mannosidase Beta gene (MANBA) where a 
significantly greater ASE bias was found in CD4+ cells compared to CD8+ cells (p=5.3x10-
6)). Amongst all the significant ASE identified the ASEeffect was always in the same direction 
in both CD4+ and CD8+ T cells. For the 18 SNVs where the evidence for ASE was significant 
in only one of the cell types (CD4 or CD8), the direction of ASE effect was consistent in the 
other cell type.  
Discussion 
In this targeted re-sequencing effort focused on coding proxies for MS associated variants we 
have been able to identify statistically significant evidence for MS risk dependent ASE in 43 
genes; thereby suggesting a potential role for these genes in the aetiology of the disease. The 
most striking novel ASE discovery was on chromosome 20q13 where the fortuitous existence 
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of two coding proxies, each tagging different LIME1 mRNA transcripts, provides us with novel 
insights in to the effects of the MS associated variant rs2256814 on LIME1 expression. LIME1 
is a lipid raft-associated transmembrane adapter protein which is highly expressed on T cells, 
interacts with Lck in mediating TCR signalling30-32 and has also been implicated in BCR 
signalling.33 Very little is known about the function of LIME1 however several mechanisms 
for its involvement in TCR signalling have been proposed. In one model LIME1 recruits 
signalling molecules for T cell activation by functioning as a docking protein at the 
immunological synapse, with phosphorylation of tyrosine residues in the cytoplasmic tail of 
LIME1 following TCR stimulation leading to the recruitment of signalling molecules including 
PI3K, SHP2, Grb2 and Gads.32 In a second model LIME1 interacts with the guanine nucleotide 
exchange factor VAV following stimulation which in turn converts Rac1 and Cdc42 to a GTP-
bound active form required for cytoskeletal rearrangement and immunological synapse 
formation.31 A role for LIME1 in controlling T cell responses by limiting the over-activation 
of antigen experienced T cells has also been suggested.30 Within LIME1 we were able to show 
that the coding proxy risk variants rs914559 and rs2236510 alter the balance of transcripts from 
the LIME1 gene. The balance of RNA transcripts in a cell is a known and important regulatory 
mechanism for controlling (amongst other pathways) the immune response, for example within 
the interferon regulatory transcription factor 3 (IRF3) gene, multiple alternatively spliced 
transcripts provide a range of regulatory mechanisms to downregulate IRF3 responses.34-36 The 
transcript structure of the LIME1 gene contained in Gencode V32 remains incomplete, so 
establishing the potential functional consequences of each transcript is not possible at present. 
Tissue specific differences in the expression of the multiple LIME1 transcripts is found in 
GTEx, with the highest expression of the non-coding LIME1 transcript captured by rs2236510 
occurring in the cerebellum, and the highest expression of the protein coding transcript 
captured by rs914559 occurring in whole blood. The results from the spliceQTL analysis in 
13 
 
GTEx V8 correlate with our data, suggesting that the SNVs we have identified either directly 
influence alternative splicing of LIME1 transcripts or tag other SNVs that do this. In the 15 cell 
types contained in the Database of Immune Cell Expression, Expression quantitative trait loci 
(eQTLs) and Epigenomics project (DICE), the expression of LIME1 was highest in CD4 cells, 
in particular in T follicular helper cells, with little to no expression seen in monocytes and B 
cells.37 Given the higher ASE bias in CD4+ T cells from MS cases, and the crucial role of this 
gene in regulating TCR signalling and T cell responses, further exploring the differential 
expression of LIME1 transcripts, particularly in the context of stimulation is required.  
Although our approach cannot distinguish cis expression QTLs from cis splice QTLs a number 
of the most extreme ASE we identified are with proxy SNVs that have previously been shown 
to alter splicing of MS relevant genes. Alongside rs1800693_G in the TNFRSF1A gene23,24 
these include the synonymous coding variant rs28445040 within the SP140 nuclear body 
protein (SP140) gene,38 rs6897932 in the interleukin-7 receptor (IL7R)39 and rs1883832 (which 
is in complete LD with the previously described rs4810485;NC_000020.11:g.46119308T>A) 
in the CD40 gene.40 All of the above SNPs (aside from rs1883832 in the CD40 gene) have also 
been implicated as sQTLs in whole blood in GTEx (V8). Validation of these previously known 
findings provide a positive control for the sensitivity and specificity of the ASE assay we have 
used.  
In several regions where more than one gene was investigated we could prioritise the 
potentially MS relevant gene. In one such region on Chromosome 12 where we were able to 
interrogate 11 suitable coding SNVs from five genes, and only found statistically significant 
evidence for ASE of the EEF1A lysine methyltransferase 3 (EEF1AKMT3, previously referred 
to as METTL21B) gene: with the MS risk haplotype reducing the expression of the gene, in 
concordance with previous findings.41 Each of these five genes might be genetically considered 
to be equally implicated by the extensive LD flanking the local MS associated variant 
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rs10431552, but the ASE analysis suggest that it is only the expression of EEF1AKMT3 that is 
altered by this risk haplotype (at least in these cell types). In other regions, pinpointing the gene 
influenced by the associated variants has been more difficult. This is most evident in the 
IKAROS family zinc finger 3 (IKZF3) - ORMDL sphingolipid biosynthesis regulator 3 
(ORMDL3) region on chromosome 17q12-q21 in the region implicated by the MS associated 
variant rs12946510 (NC_000017.11:g.39756124C>T). Two previous studies in MS have 
explored this region and reported correlation of the disease associated variant with either 
IKZF342 or gasdermin B (GSDMB)43 but neither study explored the other genes in the region. 
In our study we identified ASE for all three tested genes in the region, IKZF3, GSDMB and the 
zona pellucida binding protein gene 2 (ZPBP2), with the greatest ASE bias observed in 
GSDMB. Detailed exploration of this region in asthma established that the common genetic 
variant associated with asthma (rs7216389; NC_000017.11:g.39913696C>T r2=0.7 with the 
MS SNV rs12946510) is involved in regulating the expression of multiple genes within this 
region through nucleosome repositioning and CTCF binding.44 In such regions where extensive 
LD and multiple regulatory variants exist, correlating the disease associated variants with gene 
expression is particularly challenging and caution needs to be taken in the interpretation of the 
results.45,46 
As we only considered CD4 and CD8 T cell types we were not able to directly assess regulatory 
effects in other cell types such as monocytes and B cells. It has been shown that the difference 
in ASE between individuals is greater than it is between cell-types within an individual, thus 
suggesting a common regulatory factor across cell types within an individual.47 Interestingly 
several of our top findings relate to genes that are most highly expressed in B cells (for example 
FCRL3 and SP140). Further work is therefore required to investigate the role of these SNVs in 
different cell types. 
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Our findings confirm that many of the disease associated SNVs identified by GWAS influence 
gene expression, in many instances by altering the balance of the alternate transcripts produced. 
Although our approach only allows the assessment of ASE in genes that contain common 
coding variants in LD with associated SNVs it has proven to be informative with regard to 
allelic imbalance that could otherwise have been missed in global transcriptomic studies and 
provides a list of prioritised candidate genes. The identification of divergent ASE in specific 
mRNA transcripts of the LIME1 gene highlights the value and importance of assessing the 
expression of individual transcripts and adds to the growing evidence suggesting the 
importance of altered transcriptional balance as a mechanism by which associated variants 
exert their effects on proximal gene expression. Increasing our understanding of these 
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Figure 1. ASE in genes surrounding the MS associated SNV rs2256814. Box-whisker 
plots represent median, quartiles and 1.5x interquartile range. Statistically significant 
ASE is shown in grey, with the transcripts captured by the rs914559 SNV showing 
increased expression of the risk allele and those transcripts captured by rs2236510 





Figure 2. Replication analysis of transcript specific LIME1 regulation. Box-whisker 
plots represent median, quartiles and 1.5x interquartile range. A. Quantitative PCR 
relative gene expression capturing ENST00000487026.5 and ENST00000465591.1 
LIME1 transcripts with increased expression in rs914559_C risk allele carriers. B. 
Quantitative PCR relative gene expression capturing ENST00000493265.2 and 
ENST00000621325.1 LIME1 transcripts with decreased expression in rs2236510_T risk 
allele carriers. C. Ratio of the ENST00000487026.5/ENST00000465591.1: 
ENST00000493265.2/ENST00000621325.1 correlated with rs914559 genotype. 
 
